Hope for a Precision Medicine for ADNP Syndrome

September 24, 2026

For families affected by ADNP syndrome, the search for new treatment options is driven by both scientific progress and extraordinary determination.

 

A recent feature in RARE Revolution Magazine highlights the experiences of Genie Egerton-Warburton and her son, Rowland, alongside the work of Dr Joseph Buxbaum, Director of the Seaver Autism Centre at Mount Sinai in New York City, to advance a precision medicine for ADNP syndrome, a rare genetic neurodevelopmental condition. 

The article explores both the challenges of living with a rare disease and the power of collaboration between families, researchers, clinicians and patient advocates. It highlights how scientific discovery, combined with determination and partnership, can create new opportunities to advance treatment development for conditions that currently have few therapeutic options. 

 

The feature also highlights how Dr Buxbaum's project is being supported through the Oxford-Harrington Rare Disease Centre's Rare Disease Scholar Award programme, which aims to accelerate promising discoveries towards the clinic for people living with rare diseases. 

 

While significant work remains, the story offers a powerful example of what is possible when patients, families and researchers work together around a shared goal: creating new treatment options for people living with rare diseases and their families.